Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. reported updated ELPIS II Phase 2b results for laromestrocel, tested with Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The trial did not meet its primary endpoint, change from baseline in right ventricular ejection fraction (RVEF) at Month 12. Among 28 infants with baseline and Month 12 cardiovascular magnetic resonance data, mean RVEF decreased 2.6 percentage points in the standard-of-care group and 3.3 percentage points with laromestrocel; the difference was not statistically significant (p=0.68).
A prespecified secondary major adverse cardiac events (MACE) endpoint showed 8 events in the standard-of-care arm and 1 in the laromestrocel arm (P=0.043), a statistically significant result. No treatment-related serious adverse events were identified through 12 months. Longeveron intends to request an FDA meeting to review the results and determine potential next steps for its HLHS program.
Longeveron Inc. (LGVN) said Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down as Chief Medical Officer, effective October 14, 2026.
Longeveron Inc. Chief Financial Officer Nirav S. Jhaveri had 742 shares withheld to satisfy tax obligations in connection with vesting of a restricted stock unit award on October 1, 2026. The reported price was $2.59 per share. His reported direct position afterward was 29,258 shares, including RSUs subject to future vesting. The amounts reflect Longeveron’s one-for-ten reverse stock split undertaken in August 2026.
Longeveron Inc. (LGVN) CEO Stephen H. Willard had 1,987 shares of Class A Common Stock withheld on October 1, 2026, to satisfy tax obligations tied to vesting of a restricted stock unit award. The reported price was $2.59 per share. After the transaction, he reported 74,916 shares, including RSUs subject to future vesting. The reported amounts reflect the one-for-ten reverse stock split undertaken in August 2026.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova had 2,913 shares withheld on October 1, 2026, to satisfy tax obligations in connection with vesting of a restricted stock unit (RSU) award. The reported transaction price was $2.59 per share, and her direct holdings afterward were 68,778 shares. The reported share amounts reflect the one-for-ten reverse stock split undertaken in August 2026.
Longeveron Inc. (LGVN) General Counsel and Secretary Paul T. Lehr had 2,253 shares of Class A Common Stock withheld at $2.59 per share on October 1, 2026, to satisfy tax obligations connected with vesting of a restricted stock unit award. His reported direct holdings afterward were 83,889 shares, including RSUs subject to future vesting. The reported amounts reflect the one-for-ten reverse stock split undertaken in August 2026.
Longeveron Inc. reported that its CTO & SVP of CMC, Devin Blass, had 2,520 shares of Class A Common Stock withheld on October 1, 2026, to satisfy tax obligations tied to vesting of a restricted stock unit (RSU) award. The reported price was $2.59 per share. His direct holdings after the transaction were 68,653 shares, including RSUs subject to future vesting. The reported share amounts reflect the one-for-ten reverse stock split undertaken in August 2026.
Longeveron Inc. reported topline results from ELPIS II, a Phase 2b trial of laromestrocel alongside Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The trial did not meet its primary endpoint, change from baseline in right ventricular ejection fraction (RVEF) at Month 12: the intent-to-treat least-squares mean difference was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). A sponsor-defined exploratory composite of all-cause mortality and duration of inpatient hospitalization also was not statistically significant in the intent-to-treat population.
Treatment-emergent adverse events and serious adverse events were reported in 94.1% and 64.7% of laromestrocel-treated participants, respectively, versus 100% and 71.4% of controls. No new safety signals were identified, and investigators assessed no such events as related to laromestrocel.
The company is conducting additional analyses and intends to discuss the results with the FDA, which previously indicated willingness to meet after study completion. Longeveron initiated a review of all options to maximize shareholder value, intends to engage an investment bank as strategic advisor, and will look to implement cash-conservation measures.
Longeveron Inc. (LGVN) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq notified the company on September 11, 2026 that the Class A common stock closed at or above $1.00 for 10 consecutive business days, from August 27, 2026 through September 10, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). This follows an initial non-compliance notice in September 2025 and two 180-day grace periods extending the deadline to September 21, 2026; Nasdaq now considers the matter closed.
Longeveron Inc. (LGVN) has a new large shareholder disclosure, as Logos Global Management LP and affiliated entities reported beneficial ownership of 192,308 shares of Longeveron Class A common stock on a Schedule 13G. This represents 6.3% of the Class A shares outstanding after Longeveron’s 1-for-10 reverse stock split on August 26, 2026.
The shares are held by Logos Opportunities Fund V LP for the benefit of its investors, with Logos Global acting as investment adviser and related general partner entities and individuals Arsani William and Graham Walmsley listed as reporting persons. All reporting persons have shared voting and dispositive power over the 192,308 shares and no sole power. They state the position is not held for the purpose of changing or influencing control of Longeveron and that each disclaims beneficial ownership beyond their pecuniary interest.